Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 27-42 , July 2010

Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review

,Accepted 8 October 2009.

References 

  1. Hainsworth J, Fizazi K. Treatment for patients with unknown primary cancer and favourable prognostic factors. Semin Oncol. 2009;36:44–51
  2. Resta L, Maiorano E, Zito FA, et al. Multifocal extraovarian serous carcinoma: a histochemical and immunohistochemical study. Eur J Gynaecol Oncol. 1988;9:474–478
  3. Bloss JD, Shu-Yuan L, Buller RE, et al. Extraovarin peritoneal serous papillary carcinoma: a case–control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 1993;50:347–351
  4. Wick MR, Mills SE, Dehner LP, Bollinger DJ, Fechner RE. Serous papillary carcinomas arising from the peritoneum and ovaries. Int J Gynecol Pathol. 1989;8:179–188
  5. Schorge JO, Miller YB, Qi LG, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol. 2000;76:369–372
  6. Terai Y, Ueda M, Kumagai K, Ueki K, Ueki M. Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum. Int J Gynecol Pathol. 2000;19:354–360
  7. Moll UM, Valea F, Chumas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol. 1997;16:156–162
  8. Cass I, Baldwin RL, Fasylova E, et al. Allelotype of papillary serous peritoneal carcinomas. Gynecol Oncol. 2001;82:69–76
  9. Kowalski LD, Kanbour AI, Price FV, et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer. 1997;79:1587–1594
  10. Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol. 2001;20:341–345
  11. Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer. 2003;13:749–755
  12. Huang LW, Garrett AP, Schorge JO, et al. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol. 2000;114:93–99
  13. Huang LW, Garrett AP, Muto MG, et al. Identification of a novel 9cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol. 2000;31:367–373
  14. Quezado MM, Moskaluk CA, Bryant B, Mills SE, Merino MJ. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol. 1999;30:203–207
  15. Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1998;92:596–600
  16. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 1998;90:841–845
  17. Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study. Gynecol Oncol. 2003;89:148–154
  18. Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol. 1988;31:315–320
  19. Mills SE, Andersen WA, Fechner RE, Austin MB. Serous surface papillary carcinoma. A clinicopathologic study of ten cases and comparison with stage III/IV ovarian serous carcinoma. Am J Surg Pathol. 1988;12:827–834
  20. Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med. 1989;111:213–217
  21. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer. 1989;64:110–115
  22. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1990;75:89–95
  23. Ransom DT, Shreyaskumar RP, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer. 1990;66:1091–1094
  24. Truong LD, Maccato ML, Awalt H, Cagle PT, Schwarz MR, Kaplan AL. Serous surface carcinoma of the peritoneum: a clincopathologic study of 22 cases. Hum Pathol. 1990;21:99–110
  25. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol. 1993;51:171–174
  26. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma serous of Mullerian type: a subgroup of women presenting with peritoneal carcinomatosis. Int J Gynecol Cancer. 1994;4:43–51
  27. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer. 1995;76:429–436
  28. Baruch GB, Sivan E, Moran O, Rizel S, Menczer J, Seidman DS. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol. 1996;60:393–396
  29. Liapis A, Condi-Paphiti A, Pyrgiotis E, Zourlas PA. Ovarian surface serous papillary carcinomas: a clinicopathologic study. Eur J Gynaecol Oncol. 1996;17:79–82
  30. Taus P, Petru E, Gucer F, Pickel H, Lahousen M. Primary serous papillary carcinoma of the peritoneum: a report of 18 patients. Eur J Gynaecol Oncol. 1997;18:171–172
  31. Piver MS, Eltabakkh GH, Hempling R, Recio F, Blumenson L. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol. 1997;67:141–146
  32. Piura B, Meirovitz M, Bartfeld M, Yanai-Inbar I, Cohen Y. Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III–IV ovarian papillary serous carcinoma. J Surg Oncol. 1998;68:173–178
  33. Kennedy AW, Markman M, Webster K, et al. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol. 1998;71:288–290
  34. Eltabbakh GH, Mount SL. Lymphatic spread among women with primary peritoneal carcinoma. J Surg Oncol. 2002;81:126–131
  35. Pentheroudakis G, Briasoulis E, Karavasilis V, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?. Acta Oncol. 2005;44:155–160
  36. Choi CH, Kim TJ, Kim WY, et al. Papillary serous carcinoma in ovaries of normal size: A clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol Oncol. 2007;105:762–768
  37. Zhang C, Li XP, Cui H, Shen D, Wei L. Advanced primary peritoneal carcinoma: clinicopathologic and prognostic factor analyses. J Zhejiang Univ Sci B. 2008;9:435–440
  38. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284–5293
  39. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008;9:1191–1197
  40. Piek J, Kenemans P, Verheijen R. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718–732
  41. Spurgeon J, Cotlar AM. Cytoreductive surgery in the management of malignant ascites form adenocarcinoma of unknown primary. Curr Surg. 2005;62:500–503
  42. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a GOG study. Gynecol Oncol. 2009;112:469–474
  43. Sasaki R, Narisawa-Saito M, Yugawa T, et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 2009;19126650
  44. Lee Y, Park N. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol. 2009;112:475–480
  45. Darcy KM, Brady WE, McBroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk early stage or suboptimally-resected advanced stage epithelial ovarian cancers. A GOG study. Gynecol Oncol. 2008;111:487–495
  46. Vang R, Shih I, Salani R, Sugar E, Ayhan A, Kurman RJ. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008;32:1667–1674
  47. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35
  48. Tuefferd M, Couturier J, Penault-Llorca F, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2007;2:e1138
  49. Steffensen K, Waldstom M, Andersen RF, et al. Protein levels and gene expressions of the epidermal growth factor receptors HER1, HER2, HER3 and HER4 in benign and malignant epithelial ovarian tumours. Int J Oncol. 2008;33:195–204
  50. Olivier R, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/2 mutation carriers and events during follow-up. Br J Cancer. 2004;90:1492–1497
  51. Wang P, Shyong W, Li Y, et al. BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma. Jpn J Clin Oncol. 2000;30:343–348
  52. Li S, Han H, Resnik E, Carcangiu ML, Schwartz PE, Yang-Feng T. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol. 1993;51:21–25
  53. Schorge J, Muto M, Lee S, et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 2000;60:1361–1364
  54. Petru E, Luck H, Stuart G, Gaffney D, Millan D, Vergote I. GCIG proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol. 2009;19195765
  55. Zivanovic O, Eisenhauer E, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIc epithelial ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2008;108:287–292
  56. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer. 2003;39:1990–2005
  57. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026–2036
  58. Pentheroudakis G, Pavlidis N. Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treat Rev. 2006;32:637–644
  59. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavourable prognostic factors. Semin Oncol. 2009;36:65–74

PII: S1040-8428(09)00201-7

doi: 10.1016/j.critrevonc.2009.10.003

Critical Reviews in Oncology / Hematology
Volume 75, Issue 1 , Pages 27-42 , July 2010

Article Tools